Common Contracts
3 similar License Agreement contracts by Eiger BioPharmaceuticals, Inc.
EX-10.1 2 d207633dex101.htm EX-10.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of...License Agreement • May 5th, 2020
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of the date last signed by a party below (the “Effective Date”), by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and Eiger BioPharmaceuticals, Inc., a Delaware corporation, with offices at 350 Cambridge Ave, Suite 350, Palo Alto, CA 94306 (“Eiger”). BMS and Eiger are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT between EIGER BIOPHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • August 2nd, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
LICENSE AGREEMENT between EIGER BIOPHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • June 17th, 2016 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
